Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Issue 51 (14th December 2018)

• Record Type: Journal Article
• Authors: Anwari, Palwasha; Debellut, Frederic; Pecenka, Clint; Parwiz, Sardar M.; Clark, Andrew; Groman, Devin; Safi, Najibullah
• Is Part Of: Vaccine. Volume 36:Issue 51(2018)
• Page Start: 7769
• Page End: 7774
• Publication Date: 2018-12-14
• Subjects: Rotavirus -- Rotavirus vaccine -- Cost-effectiveness -- DALY -- Incremental cost-effectiveness ratio -- Afghanistan; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.10.058
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: Despite progress made in child survival in the past 20 years, 5.9 million children under five years died in 2015, with 9% of these deaths due to diarrhea. Rotavirus is responsible for more than a third of diarrhea deaths. In 2013, rotavirus was estimated to cause 215, 000 deaths among children under five years, including 89, 000 in Asia. As of April 2017, 92 countries worldwide have introduced rotavirus vaccination in their national immunization program. Afghanistan has applied for Gavi support to introduce rotavirus vaccination nationally. This study estimates the potential impact and cost-effectiveness of a national rotavirus immunization program in Afghanistan. Methods: This study examined the use of Rotarix® (RV1) administered using a two-dose schedule at 6 and 10 weeks of age. We used the ProVac Initiative's UNIVAC model (version 1.2.09) to evaluate the impact and cost-effectiveness of a rotavirus vaccine program compared with no vaccine over ten birth cohorts from 2017 to 2026 with a 3% annual discount rate. All monetary units are adjusted to 2017 US$. Results: Rotavirus vaccination in Afghanistan has the potential to avert more than one million cases; 660, 000 outpatient visits; approximately 50, 000 hospital admissions; 650, 000 DALYs; and 12, 000 deaths, over 10 years. Not accounting for any Gavi subsidy, rotavirus vaccination can avert DALYs at US$82/DALY from the government perspective and US$80/DALY from the societal perspective. With Gavi support, DALYs can be averted at US$29/DALY and US$31/DALY from the societal and government perspective, respectively. The average yearly cost of a rotavirus vaccination program would represent 2.8% of the total immunization budget expected in 2017 and 0.1% of total health expenditure. Conclusion: The introduction of rotavirus vaccination would be highly cost-effective in Afghanistan, and even more so with a Gavi subsidy.